Surviving and Thriving in the Long Biotech Winter
"The IPO market remains unwelcoming to biotechs and venture investors are reticent to back younger companies. In the absence of reliable funding sources, many biotechs are trying to advance their most promising programs while keeping their operations lean until they can get to a fundable milestone. Big4Bio podcast talked to CRCFO's Kevin Sarney, about the current uncertainty biotechs face, the need for capital efficiency, and how companies can best prepare for future opportunities."